411 related articles for article (PubMed ID: 7909479)
1. Bone marrow gene therapy for adenosine deaminase deficiency.
Kaptein LC; Einerhand MP; Braakman E; Valerio D; van Beusechem VW
Immunodeficiency; 1993; 4(1-4):335-45. PubMed ID: 7909479
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow gene transfer in three patients with adenosine deaminase deficiency.
Hoogerbrugge PM; van Beusechem VW; Fischer A; Debree M; le Deist F; Perignon JL; Morgan G; Gaspar B; Fairbanks LD; Skeoch CH; Moseley A; Harvey M; Levinsky RJ; Valerio D
Gene Ther; 1996 Feb; 3(2):179-83. PubMed ID: 8867866
[TBL] [Abstract][Full Text] [Related]
3. Retroviral-mediated gene transfer into mammalian cells.
Kohn DB; Kantoff PW; Eglitis MA; McLachlin JR; Moen RC; Karson E; Zwiebel JA; Nienhuis A; Karlsson S; O'Reilly R
Blood Cells; 1987; 13(1-2):285-98. PubMed ID: 3311223
[TBL] [Abstract][Full Text] [Related]
4. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy.
Hershfield MS
Semin Hematol; 1998 Oct; 35(4):291-8. PubMed ID: 9801258
[TBL] [Abstract][Full Text] [Related]
5. Expression of human adenosine deaminase in murine haematopoietic progenitor cells following retroviral transfer.
Belmont JW; Henkel-Tigges J; Chang SM; Wager-Smith K; Kellems RE; Dick JE; Magli MC; Phillips RA; Bernstein A; Caskey CT
Nature; 1986 Jul 24-30; 322(6077):385-7. PubMed ID: 3016551
[TBL] [Abstract][Full Text] [Related]
6. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy for hematopoietic and immune disorders.
Kohn DB
Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S55-8. PubMed ID: 8971410
[TBL] [Abstract][Full Text] [Related]
8. [Gene therapy for adenosine deaminase deficiency].
Sakiyama Y; Ariga T; Ohtsu M
Nihon Rinsho; 2005 Mar; 63(3):448-52. PubMed ID: 15773344
[TBL] [Abstract][Full Text] [Related]
9. Adenosine deaminase deficiency.
Hirschhorn R
Immunodefic Rev; 1990; 2(3):175-98. PubMed ID: 2078332
[TBL] [Abstract][Full Text] [Related]
10. Drug evaluation: ADA-transduced hematopoietic stem cell therapy for ADA-SCID.
Taupin P
IDrugs; 2006 Jun; 9(6):423-30. PubMed ID: 16752313
[TBL] [Abstract][Full Text] [Related]
11. Expression pattern of CD2 locus control region containing retroviral vectors in hemopoietic cells in vitro and in vivo.
Kaptein LC; Breuer M; Valerio D; van Beusechem VW
Gene Ther; 1998 Mar; 5(3):320-30. PubMed ID: 9614551
[TBL] [Abstract][Full Text] [Related]
12. [Gene therapy for adenosine deaminase deficiency].
Sakiyama Y
Hokkaido Igaku Zasshi; 1996 Jan; 71(1):27-32. PubMed ID: 8727372
[TBL] [Abstract][Full Text] [Related]
13. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
[TBL] [Abstract][Full Text] [Related]
14. Long-term in vivo expression of the MFG-ADA retroviral vector in rhesus monkeys transplanted with transduced bone marrow cells.
Kaptein LC; Van Beusechem VW; Rivière I; Mulligan RC; Valerio D
Hum Gene Ther; 1997 Sep; 8(13):1605-10. PubMed ID: 9322093
[TBL] [Abstract][Full Text] [Related]
15. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
Smogorzewska EM; Weinberg KI; Kohn DB
Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
[TBL] [Abstract][Full Text] [Related]
16. Successful lectin-separated bone marrow transplantation in adenosine deaminase deficiency-related severe immunodeficiency.
Nespoli L; Porta F; Locatelli F; Aversa F; Carotti A; Lanfranchi A; Gibardi A; Marchesi ME; Abate L; Martelli MF
Haematologica; 1990; 75(6):546-50. PubMed ID: 2098297
[TBL] [Abstract][Full Text] [Related]
17. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID.
Bordignon C; Mavilio F; Ferrari G; Servida P; Ugazio AG; Notarangelo LD; Gilboa E; Rossini S; O'Reilly RJ; Smith CA
Hum Gene Ther; 1993 Aug; 4(4):513-20. PubMed ID: 8399494
[TBL] [Abstract][Full Text] [Related]
18. Comparison of five retrovirus vectors containing the human IL-2 receptor gamma chain gene for their ability to restore T and B lymphocytes in the X-linked severe combined immunodeficiency mouse model.
Avilés Mendoza GJ; Seidel NE; Otsu M; Anderson SM; Simon-Stoos K; Herrera A; Hoogstraten-Miller S; Malech HL; Candotti F; Puck JM; Bodine DM
Mol Ther; 2001 Apr; 3(4):565-73. PubMed ID: 11319919
[TBL] [Abstract][Full Text] [Related]
19. In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency.
Carbonaro DA; Jin X; Petersen D; Wang X; Dorey F; Kil KS; Aldrich M; Blackburn MR; Kellems RE; Kohn DB
Mol Ther; 2006 Jun; 13(6):1110-20. PubMed ID: 16651028
[TBL] [Abstract][Full Text] [Related]
20. In vivo kinetics of transduced cells in peripheral T cell-directed gene therapy: role of CD8+ cells in improved immunological function in an adenosine deaminase (ADA)-SCID patient.
Kawamura N; Ariga T; Ohtsu M; Kobayashi I; Yamada M; Tame A; Furuta H; Okano M; Egashira M; Niikawa N; Kobayashi K; Sakiyama Y
J Immunol; 1999 Aug; 163(4):2256-61. PubMed ID: 10438969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
